| Literature DB >> 26653872 |
N Vijayakameswara Rao1, Hong Yeol Yoon1, Hwa Seung Han1, Hyewon Ko2, Soyoung Son2, Minchang Lee1, Hansang Lee1, Dong-Gyu Jo3, Young Mo Kang4, Jae Hyung Park1,2.
Abstract
INTRODUCTION: Hyaluronic acid (HA) has emerged as a promising applicant for the tumor-targeted delivery of various therapeutic agents. Because of its biocompatibility, biodegradability and receptor-binding properties, HA has been extensively investigated as the drug delivery carrier. In this review, recent advances in HA-based nanomedicines are discussed. AREAS COVERED: This review focuses on HA-based nanomedicines for the diagnosis and treatment of cancer. In particular, recent advances in HA-drug conjugates and HA-based nanoparticles for small molecular drug delivery are discussed. The bioreducible HA conjugates for small interfering ribonucleic acid delivery have been also discussed. EXPERT OPINION: To develop a successful HA-based nanomedicine, it has to be prepared without significant deterioration of intrinsic property of HA. The chemical modification of HA with drugs or hydrophobic moieties may reduce the binding affinity of HA to the receptors. In addition, since the HA-based nanomedicines tend to accumulate in the liver after their systemic administration, new strategies to overcome this issue have to be developed.Entities:
Keywords: Drug conjugates; hyaluronic acid; polymeric nanoparticles; tumor-targeted therapy
Mesh：
Substances：
Year: 2015 PMID： 26653872 DOI： 10.1517/17425247.2016.1112374
Source DB: PubMed Journal: Expert Opin Drug Deliv ISSN： 1742-5247 Impact factor: 6.648